Endonovo Therapeutics, Inc.
ENDV
$0.0002
$0.000.00%
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -96.68% | -48.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -96.68% | -48.34% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -98.45% | -45.87% | |||
| SG&A Expenses | -59.75% | 91.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -59.69% | 90.74% | |||
| Operating Income | 58.21% | -113.74% | |||
| Income Before Tax | -137.13% | -71.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -137.13% | -71.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -137.13% | -71.46% | |||
| EBIT | 58.21% | -113.74% | |||
| EBITDA | 67.91% | -163.76% | |||
| EPS Basic | -134.67% | -73.96% | |||
| Normalized Basic EPS | -136.36% | -75.28% | |||
| EPS Diluted | -225.00% | -166.67% | |||
| Normalized Diluted EPS | -277.78% | -65.38% | |||
| Average Basic Shares Outstanding | 7.98% | 9.94% | |||
| Average Diluted Shares Outstanding | -77.91% | -22.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
